Brain Tumor Research
At Stanford Brain Tumor Center, we have a comprehensive program that encompasses basic, translational, and clinical research.
The Gray Laboratory develops first-in-class chemical probes that are used to gain new biological insights into cellular processes that drive cancer and other diseases, and to pharmacologically validate potential clinically relevant targets.
The Bertozzi lab focuses on creating new platform technologies, as well as applying chemical approaches to study systems that elude more conventional methods of biological inquiry. Examples of technologies that drive our research are bioorthogonal chemistries, site-specific protein modification methods, and synthetic glycopolymers that emulate cell-surface glycoproteins.
Our Lab investigates the outcomes of patients affected with brain, skull base and spine tumors. The goal of the laboratory is to improve patients’ care and outcome by analyzing clinical data from thousands of patients treated at our institution, with surgery as well as with other innovative treatments, such as stereotactic radiosurgery.
Epidemiology & Population Health
The Melissa Bondy Lab has a comprehensive research focus along the continuum of cancer prevention and population sciences. Research in the lab focuses on the molecular and genetic epidemiology of nearly all cancers, including breast, brain, colon, esophageal, pancreas, lung, pediatric, ovarian and prostate, and tobacco-related cancers.
Immunology & Stem Cell Biology
Our goal is to understand the mechanisms regulating the development of human systems (both embryonic and adult). In particular, we are interested in clarifying the roles of both protein coding genes as well as pathobiology (disease state or pathogen) known to be uniquely human – therefore, not analogously studied in model organisms.
The Satpathy Lab is focused on developing and applying novel genome-scale technologies to study fundamental principles of the immune system in health, infection, and cancer.
The Weissman Lab studies stem cell biology in health and disease and the development of macrophage-based immunotherapy. In leukemic cells, the lab discovered up-regulation of CD47 that acts as a ‘don’t eat me signal for macrophages and allows cancer cells to evade an immune response. They developed anti-CD47 as a cancer immunotherapy and continue to investigate how macrophages recognize and eliminate unhealthy cells, with a prospect of advancing medicine.
The Lim Lab is focused on understanding basic mechanisms of immunosuppression in GBM. They extensively study both the myeloid and lymphocyte compartments to examine key players in the adaptive process utilized by GBM to avoid immune surveillance and elimination.
The Monje Lab studies the molecular and cellular mechanisms of postnatal neurodevelopment. This includes microenvironmental influences on neural precursor cell fate choice in normal neurodevelopment and in disease states.
The Mackall lab seeks to discover fundamental principles that control tumor:immune interactions and to apply these insights to develop novel immunotherapies for cancer.
The goal of the NeuroTraIn Center is to introduce novel anatomical concepts and innovative surgical technique into real surgical practice. We are teaching the next generation of neurosurgeons the art of microsurgical dissection to spread this knowledge and to influence Neurosurgery worldwide.
The Li Laboratory studies the biology of brain tumors with the goal of developing novel therapeutics for the treatment of malignant brain tumors and translating that research into clinical trials. Currently we are studying a variety of different protein pathways that we hypothesize to be important players in glioblastoma formation and growth.
The Petritsch lab broadly investigates underlying causes for the intra-tumoral heterogeneity and immune suppression in brain tumors from a developmental neurobiology context. Defects in cell fate control could explain many key defects present in brain tumors and an understanding of how brain cells control the fate of their progeny may identify novel points of vulnerabilities to target with therapeutics. Of special emphasis, we study the establishment of cell fates within normal hierarchical brain lineages for comparison to the dysregulated cell-fate hierarchies seen in brain tumors.
The Stanford Brain Metastases Consortium is a unique partnership between scientists, physicians and surgeons from across the Stanford community, that brings together experts in research and clinical care of brain metastases
The Gephart laboratory accelerates translational brain tumor research, combining innovative techniques in genetics and cancer biology. They use novel genetic sequencing methods and modeling to understand how cancer grows in the brain, inadvertently supported by native brain cells.